(Submitted for publication July 13, 1962 ; accepted September 8, 1962) Elevated concentrations of plasma transcortin have been shown to exist during pregnancy or after the administration of estrogens and to be accompanied by almost concomitant increases in the levels of plasma cortisol (1) (2) (3) (4) . 1 The latter change has been ascribed to the higher transcortin capacity to bind cortisol. Using these indirect evidences, we have postulated that transcortinbound cortisol is 1) biologically inactive and 2) unavailable for catabolism. The first hypothesis explains the lack of hypercorticism in face of high cortisol levels in pregnancy and in estrogentreated subjects, and the second hypothesis the slower metabolism of cortisol in the above subjects (4) (5) (6) (7) (8) . The verification of the first hypothesis has recently been published from our laboratory and is based on the observation that transcortin prevents glycogen deposition in adrenalectomized mice treated with cortisol (9) . In this paper we wish to report evidence in support of the second hypothesis, i.e., that transcortin prevents the catabolism of cortisol by human or rat liver homogeniates or microsomes.
METHODS AND MATERIALS
Human liver was obtained at operation and processed immediately at 50 C. Human or rat liver homogenates (10 per cent) were made in 0.05 M phosphate buffer at pH 7.4. For the isolation of microsomes a 10 per cent homogenate in 0.25 M sucrose was prepared by hand usinig a Potter-Elvehj em homogenizer. After sedimentation of the nuclei and mitochondria, the microsomes were collected as sediment at 104,000 X G. Purification of transcortin. Over 600 ml of plasma from subjects treated with estrogens was dialyzed against 2 volumes of water overnight in the cold room. After adjusting the pH of the dialyzed plasma to 5.0, it was clarified by centrifugation and then placed on a 5 X 35 cm column of diethylaminoethylcellulose (DEAEC), which had been previously conditioned to 0.05 M sodium chloride at pH 5.0. After the plasma had all entered the resin, the column was washed with 0.05 Ml sodium chloride, pH 5.0, until the optical density of the eluate at 280 myt fell to 0.6. A gradient was then started with the following conditions: in the mixing chamber 470 ml of 0.05 M sodium chloride, at pH 5.0; in the reservoir 0.2 M NaH2PO4-0.075 M sodium chloride, pH 5.0, 1: 10; R = Rout= 6 to 10 ml per minute; 110 30-ml fractions were collected. The column was run at room temperature (25 to 28°C).
Some protein is removed by lowering the ionic strength and pH, but the bulk of the protein, including the albumin, passes through the column and is discarded before the gradient elution is commenced. When the gradient is started, the blue zone, due presumably to caeruloplasmin, should be at the top of the column; at the completion. of the gradient, it should be coming off. The transcortin moves just ahead of the caeruloplasmin.
The eluate was analyzed for protein by absorption at 280 mA, with ovalbumin as a standard. The transcortin area was localized either by the addition of 4-C4-cortisol prior to chromatography and determination of the radioactivity in each tube by gas-flow counting, or by determination of binding by equilibrium dialysis at pH 7.0 (1).
To concentrate the protein, Sephadex G-75 or G-25 was used, 30 g per 600 ml. After standing for 10 min-51 In previous studies it was shown that pregnancy plasma or that obtained from patients after estrogen therapy contained more transcortin than normal plasma (1-3). In the next series of experiments plasmas obtained from various subjects were incubated with either human or rat liver microsomes. In each instance less cortisol is metabolized in the presence of plasma from pregnant women or subjects given estrogens than was observed in the presence of normal plasma or no plasma at all (Table IV) . Since in the former conditions the plasma cortisol levels are elevated. 
DISCUSSION
The prevention of cortisol-induced glycogen deposition in the livers of adrenalectomized mice by the administration of transcortin supported our hypothesis that transcortin-bound cortisol appears to be biologically inactive (9) . Implicit in this hypothesis are two postulates: 1) that the biologically effective levels of cortisol in the body are not related to the total plasma concentration of the steroid, but to that which is not bound to transcortin, and 2) that the transcortin-bound cortisol should not be available for catabolism. The latter biologic potential of transcortin has been demonstrated in the experiments presented. In previously published investigations it was shown that cortisol is metabolized at a greatly reduced rate in subjects with high concentrations of plasma transcortin (4, (6) (7) (8) . These results were interpreted as indicating that the much slower metabolism of cortisol was due to its being bound to transcortin and thus rendered unavailable for catabolism by the liver. The in vitro experiments presented in the present paper lend further support to the hypothesis. The inability of rat or liver homogenates or microsomes to reduce the cortisol molecule efficiently in the presence of transcortin (either in concentrated form or in transcortin-rich plasma) points to the ability of transcortin to bind cortisol much more strongly than the enzyme systems in the liver. On the other hand, human serum albumin was not capable of competing with the liver enzyme systems for cortisol, indicating a low affinity of the albumin for the steroid, as has been previously reported (1) .
Even 
SUMMARY
In an in vitro system, employing either human or rat liver microsomes, transcortin competes efficiently for cortisol with the enzyme systems responsible for the reduction of the steroid, resulting in lesser metabolism of cortisol in the presence of transcortin. The addition of transcortin-rich plasma (pregnancy, estrogen-treated subjects) to the incubation gave results similar to those obtained with purified transcortin. The partial purification of the latter is described. The results obtained bear on the interpretation of the effects of transcortin on cortisol metabolism in vivo.
